Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy

Journal of the National Cancer Institute

Volumn 89, Issue 8, 1997, Pages 577-580

  Souhami, Robert L ^a   Spiro, Stephen G ^a   Rudd, Robin M ^b   Ruiz De Elvira, Mary Carmen ^a   James, Lindsay E ^a   Gower, Nicole H ^a   Lamont, Alan ^c   Harper, Peter G ^d,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

EID: 0030946011     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.8.577     Document Type: Article

References (17)

1. Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Sub-committee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 1990;61:584-9.
2. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party. Br J Cancer 1996;73:406-13.
3. Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG, Tobias JS. The prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 1985;45:2878-82.
4. Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research [published erratum appears in Br J Cancer 1990;62:550]. Br J Cancer 1990;61:597-604.
5. Carney DN, Grogan L, Smit EF, Harford P, Berendsen HH, Postmus PE. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 1990;17(1 Suppl 2):49-53.
6. Smit EF, Carney DN, Harford P, Sleijfer DT, Postmus PE. A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 1989;44:631-3.
7. Carney DN, Keane M, Grogan L. Oral etoposide in small cell lung cancer. Semin Oncol 1992;19(6 Suppl 14):40-4.
8. Clark PI, Cottier B. The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol 1992;19(6 suppl 14):36-9.
9. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990;8:1613-7.
10. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996;348: 563-6.
11. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Publ No. 148. Geneva: WHO, 1979.
12. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990;62:1034-8.
13. Geddes DM, Dones L, Hill E, Law K, Harper PG, Spiro SG, et al. Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. Eur J Cancer 1990;26:484-92.
14. Pocock SJ. Clinical trials: a practical approach. Chicago (IL): John Wiley & Sons. 1983:84-7.
15. Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993;11: 374-7.
16. Harvey VJ, Slevin ML, Joel SP, Smythe MM, Johnston A, Wrigley PF. Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol 1985;21:1315-9.
17. Slevin ML. Low-dose oral etoposide: a new role for an old drug? [editorial]. J Clin Oncol 1990;8:1607-9.